Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 heart disease and stroke statistics: A report of US and global data from the American heart association. Circulation. 2024;149:e347–913.

Article  PubMed  Google Scholar 

Mensah GA, Fuster V, Murray CJL, Roth GA, null null, Mensah GA et al. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. J Am Coll Cardiol. 2023;82:2350–473.

Goh RSJ, Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Kueh MTW, et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, central Asia, and high-income Asia Pacific regions. Lancet Reg Health West Pac. 2024;49:101138.

PubMed  PubMed Central  Google Scholar 

Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2024:zwae281.

Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, et al. Underutilization of High-Intensity Statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65:270–7.

Article  PubMed  Google Scholar 

Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al. Distribution of estimated 10-Year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016;134:1419–29.

Article  PubMed  Google Scholar 

Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, et al. C-Reactive protein, but not Low-Density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive Statin therapy. Circulation. 2013;128:2395–403.

Article  CAS  PubMed  Google Scholar 

Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137:2551–3.

Article  PubMed  Google Scholar 

Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.

Article  PubMed  PubMed Central  Google Scholar 

Nurmohamed NS, Kraaijenhof JM, Mayr M, Nicholls SJ, Koenig W, Catapano AL, et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J. 2023;44:1594–607.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hinterwirth H, Stegemann C, Mayr M, Lipidomics. Circulation: Cardiovasc Genet. 2014;7:941–54.

CAS  Google Scholar 

Stegemann C, Drozdov I, Shalhoub J, Humphries J, Ladroue C, Didangelos A, et al. Comp Lipidom Profiling Hum Atherosclerotic Plaques Circulation: Cardiovasc Genet. 2011;4:232–42.

CAS  Google Scholar 

Martens FK, Tonk ECM, Janssens ACJW. Evaluation of polygenic risk models using multiple performance measures: a critical assessment of discordant results. Genet Sci. 2019;21:391–7.

Google Scholar 

Ottosson F, Emami Khoonsari P, Gerl MJ, Simons K, Melander O, Fernandez C. A plasma lipid signature predicts incident coronary artery disease. Int J Cardiol. 2021;331:249–54.

Article  PubMed  Google Scholar 

Poss AM, Maschek JA, Cox JE, Hauner BJ, Hopkins PN, Hunt SC, et al. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J Clin Invest. 2020;130:1363–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu D, Vernon ST, D’Agostino Z, Wu J, Giles C, Chan AS, et al. Lipidomics profiling and risk of coronary artery disease in the BioHEART-CT discovery cohort. Biomolecules. 2023;13:917.

Article  PubMed  PubMed Central  Google Scholar 

Wu J, Giles C, Dakic A, Beyene HB, Huynh K, Wang T, et al. Lipidomic risk score to enhance cardiovascular risk stratification for primary prevention. J Am Coll Cardiol. 2024;84:434–46.

Article  CAS  PubMed  Google Scholar 

Mundra PA, Barlow CK, Nestel PJ, Barnes EH, Kirby A, Thompson P, et al. Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention. JCI Insight. 2018;3:e121326.

Article  PubMed  PubMed Central  Google Scholar 

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

Article  Google Scholar 

Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently Lowered by Simvastatin and PCSK9 deficiency. J Clin Endocrinol Metabolism. 2014;99:E45–52.

Article  Google Scholar 

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37:1967–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hilvo M, Meikle PJ, Pedersen ER, Tell GS, Dhar I, Brenner H, et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk Estimation score for coronary artery disease patients. Eur Heart J. 2020;41:371–80.

Article  CAS  PubMed  Google Scholar 

Hilvo M, Wallentin L, Ghukasyan Lakic T, Held C, Kauhanen D, Jylhä A, et al. Prediction of residual risk by Ceramide-Phospholipid score in patients with stable coronary heart disease on optimal medical therapy. J Am Heart Association. 2020;9:e015258.

Article  CAS  Google Scholar 

Bismuth J, Lin P, Yao Q, Chen C, Ceramide. A common pathway for atherosclerosis? Atherosclerosis. 2008;196:497–504.

Article  CAS  PubMed  Google Scholar 

Jiang X, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M et al. Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000; 20:2614–8.

Holland WL, Brozinick JT, Wang L-P, Hawkins ED, Sargent KM, Liu Y, et al. Inhibition of ceramide synthesis ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced insulin resistance. Cell Metabol. 2007;5:167–79.

Article  CAS  Google Scholar 

Ruuth M, Nguyen SD, Vihervaara T, Hilvo M, Laajala TD, Kondadi PK, et al. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 2018;39:2562–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient Mice *. J Biol Chem. 2005;280:10284–9.

Article  CAS  PubMed  Google Scholar 

Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021;18:701–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Genin MJ, Gonzalez Valcarcel IC, Holloway WG, Lamar J, Mosior M, Hawkins E, et al. Imidazopyridine and Pyrazolopiperidine derivatives as novel inhibitors of Serine palmitoyl transferase. J Med Chem. 2016;59:5904–10.

Article  CAS  PubMed  Google Scholar 

Salaun E, Lefeuvre-Orfila L, Cavey T, Martin B, Turlin B, Ropert M, et al. Myriocin prevents muscle ceramide accumulation but not muscle fiber atrophy during short-term mechanical unloading. J Appl Physiol. 2016;120:178–87.

Article  CAS  PubMed  Google Scholar 

Lankinen M, Schwab U, Erkkilä A, Seppänen-Laakso T, Hannila M-L, Mussalo H et al. C Zhang editor 2009 Fatty fish intake decreases lipids related to inflammation and insulin Signaling—A lipidomics approach. PLoS ONE 4 e5258.

Article  PubMed  PubMed Central  Google Scholar 

Wang DD, Toledo E, Hruby A, Rosner BA, Willett WC, Sun Q, et al. Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the PREDIMED trial (Prevención Con Dieta Mediterránea). Circulation. 2017;135:2028–40.

Article  CAS  PubMed  PubMed Central  Google Scholar